Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

Author： Coleman R.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.127, Iss.2, 2011-06, pp. : 429-438

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Method of Detection of Initial Recurrence of Stage II/III Cutaneous Melanoma: Analysis of the Utility of Follow-Up Staging

By Meyers Michael  

Annals of Surgical Oncology, Vol. 16, Iss. 4, 2009-04 ,pp. : 941-947

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel Followed by Epirubicin in Stage II/III Breast Cancer

By Ramaswamy Bhuvaneswari   Povoski Steven   Rhoades Chris   Allen Joan   Hauger Marsha   Young Donn   Burak William   Farrar William   Yee Lisa   Kendra Kari   Somasundaram Sivagurunathan   Orlowski Robert   Shapiro Charles  

Breast Cancer Research and Treatment, Vol. 93, Iss. 1, 2005-09 ,pp. : 67-74

Springer Publishing Company

Access to resources Recommend Favorite

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

By Somlo G.   Martel C.   Lau S.   Frankel P.   Ruel C.   Gu L.   Hurria A.   Chung C.   Luu T.   Morgan R.   Leong L.   Koczywas M.   McNamara M.   Russell C.   Kane S.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 899-906

Springer Publishing Company

Access to resources Recommend Favorite

Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact?

By Kumar N.B.  

Breast Cancer Research and Treatment, Vol. 44, Iss. 2, 1997-06 ,pp. : 135-143

Springer Publishing Company

Access to resources Recommend Favorite

Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer

By Buzdar A.  

Breast Cancer Research and Treatment, Vol. 73, Iss. 2, 2002-05 ,pp. : 161-175

Springer Publishing Company

Access to resources Recommend Favorite